

**SHORT, MEDIUM AND LONG TERM PLAN OF ACTION TOWARDS SELF RELIANCE OF VACCINES
IN THE OIC REGION (2014-2022)**

Implementation Plan

Short Term Actions (2014-2016):

No	Action	Target / KPI	Timeline	Implementation Partners	Remarks
1.	Creation and updating database on vaccine needs, potential resources such as research capability, manufacturing capability and capacity (production, testing, clinical study and distribution)	a. Establishment of web-base form b. Training/ Workshop on web implementation c. Implementation monitoring	Q2 2014 Q3 2014 Q4 2014 annually	OIC Member States	OIC GS select the web provider Each member state appoint PIC
2.	Establishment of Vaccine Manufacturers Group with the task to coordinate collaboration in vaccine manufacturing between each other (toll manufacturing, under license and supply agreement, etc)	a. Establishment of OIC VMG SC and Secretariat. b. MoU - Agreement on collaboration (vaccine or material supply, production, testing, clinical trial etc)	2014 2016	Vaccine Manufacturers and OIC GS	
3.	National Capability Building through: Training, Knowledge and Experience Sharing (involvement of OIC vaccine manufacturers, WHO and other well known institutes in Europe to arrange for training and workshops).	a. Annual Program for Workshop on Vaccine Manufacturing standard with involvement of WHO and others b. Benchmark and visit facilities	2014 - 2016 2015	Vaccine Manufacturers	

4.	Development of Quality Management System (QMS)	Implementation of : documentation system, calibration – validation, change control, deviation management, corrective and preventive, preventive maintenance, storage and distribution,	2015 - 2016	Vaccine Manufacturers	could be integrated with point 3a.
5.	Collaboration and Transfer of Technology to develop the Fill and Finish Production Capabilities; provide intermediate material and support expertise by manufacturer which has been recognized by WHO	a. Agreement on material supply and technology transfer of FFP b. Fill and Finish capabilities of OIC Vaccine Manufacturers	2014 - 2016	Vaccine Manufacturers	
6.	Preparation of technical and economical feasibility studies	Feasibility study report	2015	SESRIC	
7.	Pooling Procurement Mechanism within the OIC	a. Approved procedure of pooling procurement b. Implementation monitoring	2014 2015 periodic	OIC GS and Member States	
8.	Participation in the process of development and harmonization of standards on vaccines within the OIC in accordance with the WHO standards	a. Participate in NRA workshop as speaker or panelist b. Position paper for global issues	2014 – 2016	Technical Committee	
9.	National Regulatory Authority has to be recognized as fully functional by WHO. Enhance understanding among	a. support NRA function related to manufacturing and distribution process	2014 - 2016	OIC GS and Member States	could be inline with point 8.

	OIC Member States on the importance of Strengthening NRA Function on SRVPA to ensure quality, safety and efficacy of medicines and vaccines				
10.	Good distribution practice (GDP) for vaccine to increase immunization coverage (meeting WHO standards for maintaining of cold chain).	a. Workshop on GDP b. Implementation monitoring	2014 - 2016	Vaccine Manufacturers	could be integrated with point 4.

Medium Term Actions (2017-2019):

No	Action	Target / KPI	Timeline	Implementation Partners	Remarks
1.	Increase capacity for vaccine production.	a. Fulfill vaccines need in the region b. Fill the gap of vaccine s need in all OIC countries	2017 2019	Vaccine Manufacturers	Supported by IDB for investment
2.	Collaboration and joint investment in advanced bio-technology	a. Agreement in research collaboration b. Agreement in joint investment	2017 2019	Vaccine Manufacturers and Member States	
3.	Strengthening cooperation on capability development	a. Agreement on development of new vaccine b. Working Group for new product development	2017 - 2020	Vaccine Manufacturers	could be integrated with point 2.

4.	Strengthening cooperation with international partners including WHO, UNICEF and GAVI.	a. Involve in regulation concept b. Placement OIC representative in the Global Organization.	2017 2019	OIC GS, Member States and Member States	
5.	Strengthening standards in accordance with WHO requirements.	a. WHO recognition for NRA and Manufacturers	2020	Member States and Vaccines Manufacturers	

Long Term Actions (2020 and beyond):

No	Action	Target / KPI	Timeline	Implementation Partners	Remarks
1.	Establishment of OIC Research Center for new products development to anticipate new diseases by using potential resources among OIC member states which have been recognized by WHO	a. Research Facility for OIC members establishment b. Roadmap of R&D c. New product launching	2020 2021	Member States	Supported by IDB or other global fund organizations
2.	Cooperation for joint development and joint production of raw materials (bulk antigens).	a. Agreement on produce and supply raw material. b. Agreement on manufacture and supply intermediate product c. Agreement on supply final product	2020 2021 2022	Vaccine Manufacturers	
3.	Further expansion of OIC indigenous manufacturing capacity.	a. New manufacturers in each region	2020 - 2022	Vaccine Manufacturers	Supported by Government in region